Pulmatrix EBITDA 2014-2022 | PULM
Pulmatrix ebitda from 2014 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Pulmatrix Annual EBITDA
(Millions of US $) |
| 2021 |
$-15 |
| 2020 |
$-9 |
| 2019 |
$-13 |
| 2018 |
$-20 |
| 2017 |
$-17 |
| 2016 |
$-20 |
| 2015 |
$-23 |
| 2014 |
$-9 |
| 2014 |
$-3 |
| 2013 |
$-0 |
| 2013 |
$-1 |
| 2012 |
$-1 |
Pulmatrix Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-5 |
| 2021-12-31 |
$-4 |
| 2021-09-30 |
$-4 |
| 2021-06-30 |
$-4 |
| 2021-03-31 |
$-4 |
| 2020-12-31 |
$-2 |
| 2020-09-30 |
$-1 |
| 2020-06-30 |
$-1 |
| 2020-03-31 |
$-5 |
| 2019-12-31 |
$-4 |
| 2019-09-30 |
$-3 |
| 2019-06-30 |
$-1 |
| 2019-03-31 |
$-4 |
| 2018-12-31 |
$-4 |
| 2018-09-30 |
$-5 |
| 2018-06-30 |
$-6 |
| 2018-03-31 |
$-5 |
| 2017-12-31 |
$-4 |
| 2017-09-30 |
$-4 |
| 2017-06-30 |
$-5 |
| 2017-03-31 |
$-3 |
| 2016-12-31 |
$-2 |
| 2016-09-30 |
$-3 |
| 2016-06-30 |
$-9 |
| 2016-03-31 |
$-5 |
| 2015-12-31 |
$-4 |
| 2015-09-30 |
$-5 |
| 2015-06-30 |
$-11 |
| 2015-03-31 |
$-3 |
| 2014-12-31 |
$-2 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
$-2 |
| 2014-03-31 |
$-1 |
| 2013-12-31 |
$-1 |
| 2013-09-30 |
$-1 |
| 2013-06-30 |
$-0 |
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.017B |
$0.005B |
|
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|
